# Ginkgo Bioworks Holdings, Inc.: overview

DNA · NYSE · CIK 1830214 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dna.md) · [Financials](/companies/dna/financials.md) · [Filings](/companies/dna/filings.md) · [Insiders](/companies/dna/insiders.md)

Latest reported revenue: [$20.2m](/filings/0001628280-26-054298.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054298).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [89.0](/filings/0001628280-25-050193.md) | [43.8 d](/filings/0001628280-26-012346.md) | [38.2](/filings/0001628280-26-032116.md) | [39.1](/filings/0001628280-26-054298.md) | [38.8](/filings/0001628280-25-050193.md) | [33.4 d](/filings/0001628280-26-012346.md) | [19.5](/filings/0001628280-26-032116.md) | [20.2](/filings/0001628280-26-054298.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(62.0%)](/filings/0001628280-25-050193.md) | [(236.3%) d](/filings/0001628280-26-012346.md) | [(211.8%)](/filings/0001628280-26-032116.md) | [(148.6%)](/filings/0001628280-26-054298.md) | [(231.8%)](/filings/0001628280-25-050193.md) | [(211.9%) d](/filings/0001628280-26-012346.md) | [(366.5%)](/filings/0001628280-26-032116.md) | [(290.5%)](/filings/0001628280-26-054298.md) |
| Net margin | % | [(63.3%)](/filings/0001628280-25-050193.md) | [(245.2%) d](/filings/0001628280-26-012346.md) | [(237.9%)](/filings/0001628280-26-032116.md) | [(154.1%)](/filings/0001628280-26-054298.md) | [(207.9%)](/filings/0001628280-25-050193.md) | [(241.8%) d](/filings/0001628280-26-012346.md) | [(424.1%)](/filings/0001628280-26-032116.md) | [(231.7%)](/filings/0001628280-26-054298.md) |
| Diluted EPS | $ per share | [(1.08)](/filings/0001628280-25-050193.md) | not reported | [(1.68)](/filings/0001628280-25-022761.md) | [(1.10)](/filings/0001628280-25-038982.md) | [(1.45)](/filings/0001628280-25-050193.md) | not reported | not reported | not reported |
| Free cash flow | $m | [(119) d](/filings/0001628280-25-050193.md) | [(56.1) d](/filings/0001628280-26-012346.md) | [(59.1)](/filings/0001628280-26-032116.md) | [(40.3) d](/filings/0001628280-26-054298.md) | [(31.6) d](/filings/0001628280-25-050193.md) | [(47.7) d](/filings/0001628280-26-012346.md) | [(48.6)](/filings/0001628280-26-032116.md) | [(46.9) d](/filings/0001628280-26-054298.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [314](/filings/0001628280-24-008052.md) | [478](/filings/0001628280-25-007819.md) | [251](/filings/0001628280-26-012346.md) | [227](/filings/0001628280-26-012346.md) | [170](/filings/0001628280-26-012346.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(582.6%)](/filings/0001628280-24-008052.md) | [(462.4%)](/filings/0001628280-25-007819.md) | [(343.8%)](/filings/0001628280-26-012346.md) | [(246.5%)](/filings/0001628280-26-012346.md) | [(185.3%)](/filings/0001628280-26-012346.md) |
| Net margin | % | [(583.1%)](/filings/0001628280-24-008052.md) | [(440.6%)](/filings/0001628280-25-007819.md) | [(355.1%)](/filings/0001628280-26-012346.md) | [(240.9%)](/filings/0001628280-26-012346.md) | [(183.8%)](/filings/0001628280-26-012346.md) |
| Diluted EPS | $ per share | [(1.39)](/filings/0001628280-24-008052.md) | [(50.20)](/filings/0001628280-25-007819.md) | [(18.37)](/filings/0001628280-26-012346.md) | [(10.54)](/filings/0001628280-26-012346.md) | [(5.64)](/filings/0001628280-26-012346.md) |
| Free cash flow | $m | [(310)](/filings/0001628280-24-008052.md) | [(304)](/filings/0001628280-25-007819.md) | [(336)](/filings/0001628280-26-012346.md) | [(382)](/filings/0001628280-26-012346.md) | [(179)](/filings/0001628280-26-012346.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dna/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $42.4m | 4,282,903 |  | Added +640,556 |
| [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $35.4m | 3,577,128 |  | Unchanged |
| [Erste Asset Management GmbH](/funds/2024532.md) | 2026-06-30 | $25.9m | 2,536,939 |  | Added +589,211 |
| [BAILLIE GIFFORD & CO](/funds/1088875.md) | 2026-06-30 | $23.7m | 2,391,649 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $20.7m | 2,087,293 |  | Added +172,865 |
| [Anchorage Capital Group, L.L.C.](/funds/1300714.md) | 2026-06-30 | $17.3m | 1,746,363 |  | Unchanged |
| [Legal & General Group Plc](/funds/764068.md) | 2026-06-30 | $16.5m | 1,669,419 |  | Added +7,832 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $14.6m | 1,472,370 |  | Added +125,711 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $12.1m | 1,222,016 |  | Added +212,654 |
| [FORBES J M & CO LLP](/funds/1067532.md) | 2026-06-30 | $9.9m | 999,911 |  | Reduced −28,480 |

## Recent filings

[All 1,569 filings](/companies/dna/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:09 ET | [10-Q](/filings/0001628280-26-054298.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054298 |
| 2026-08-05 | 16:06 ET | [8-K](/filings/0001628280-26-053319.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053319 |
| 2026-07-30 | 16:06 ET | [8-K](/filings/0001628280-26-051041.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-051041 |
| 2026-06-12 | 17:00 ET | [8-K](/filings/0001628280-26-042932.md) | 5.07 Shareholder vote results | 0001628280-26-042932 |
| 2026-05-07 | 16:13 ET | [10-Q](/filings/0001628280-26-032116.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032116 |
| 2026-05-07 | 16:09 ET | [8-K](/filings/0001628280-26-032093.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-032093 |
| 2026-04-29 | 16:10 ET | [DEF 14A](/filings/0001628280-26-028377.md) | Proxy statement, period 2026-06-11 | 0001628280-26-028377 |
| 2026-04-07 | 17:02 ET | [8-K](/filings/0001628280-26-024101.md) | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001628280-26-024101 |
| 2026-02-27 | 21:56 ET | [8-K](/filings/0001628280-26-012552.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001628280-26-012552 |
| 2026-02-26 | 16:34 ET | [10-K](/filings/0001628280-26-012346.md) | Annual report, period 2025-12-31 | 0001628280-26-012346 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012346.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/76a59f93-0c11-48d9-aab1-94104cf11d1d)

## About the filer

- CIK: 1830214
- Tickers: DNA
- Exchange: NYSE
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:07 ET. No prices; not investment advice.